Chicago—Urea-based skin creams can reduce the incidence of hand–foot skin reactions (HFSR) in patients treated with sorafenib (Nexavar, Bayer), according to results from a large Phase II, open-label, randomized study. An example of this skin cream is Eucerin (Beiersdorf, Inc), a commonly available product.
The finding, reported at the annual meeting of the American Society of Clinical Oncology (abstract 4008), has already spurred practitioners to make changes.
“I would definitely recommend Eucerin cream in patients who are on sorafenib,” said Ed Chu, MD, chief of Hematology/Oncology and deputy director of the University of Pittsburgh Cancer Institute, who was not involved with the study. “It might also be interesting to use Eucerin cream with other drugs that are associated with hand–foot syndrome, such as the oral fluoropyrimidine Xeloda [Roche], and I’ve already discussed this with my nurse and mid-level provider,” he said.
Examples of hand-foot syndrome.
Hand–foot skin reactions occur in 21% of patients who are treated with sorafenib for unresectable hepatocellular carcinoma and 30% of patients who receive this drug for advanced renal cell carcinoma.
Investigators of the new study, which was conducted at 64 centers in China, enrolled patients with advanced hepatocellular carcinoma who were sorafenib-naive. Approximately 900 patients were given sorafenib and randomized to concomitant best supportive care (BSC) or BSC plus urea-based skin cream. The treatment arms were well balanced in terms of baseline patient characteristics.
Patients who were treated with the skin cream had a significantly lower incidence of all-grade HFSR within 12 weeks (56.0% vs. 73.6%; P<0 .0001=".0001" 29.2="29.2" 2="2" as="as" em="em" grade="grade" hfsr="hfsr" nbsp="nbsp" vs.="vs." well="well">P